how are glp-1 drugs made and Eating Disorders: A Hidden Risk in the Weight Loss Revolution – The Chicago Council on Science and Technology GLP-1 Drug Side Effects May

Ghazanfar H, Javed N, Qasim A, Sosa F, Altaf F, Khan S, et al

Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate

At the American Diabetes Association (ADA) 2025 conference: Eli Lilly presented bimagrumab plus semaglutide for improved muscle retention

Visualization: pela Volanek

The study was funded by the National Institute of Child Health and Development (grant R01 HD097778)